» Articles » PMID: 37765087

An Update on the Therapeutic Potential of Antimicrobial Peptides Against Infections

Overview
Publisher MDPI
Specialty Chemistry
Date 2023 Sep 28
PMID 37765087
Authors
Affiliations
Soon will be listed here.
Abstract

The rise in antibiotic-resistant strains of clinically important pathogens is a major threat to global health. The World Health Organization (WHO) has recognized the urgent need to develop alternative treatments to address the growing list of priority pathogens. Antimicrobial peptides (AMPs) rank among the suggested options with proven activity and high potential to be developed into effective drugs. Many AMPs are naturally produced by living organisms protecting the host against pathogens as a part of their innate immunity. Mechanisms associated with AMP actions include cell membrane disruption, cell wall weakening, protein synthesis inhibition, and interference in nucleic acid dynamics, inducing apoptosis and necrosis. is a critical pathogen, as severe clinical implications have developed from isolates resistant to current antibiotic treatments and conventional control procedures, such as UV light, disinfectants, and drying. Here, we review the natural AMPs representing primary candidates for new anti- drugs in post-antibiotic-era and present computational tools to develop the next generation of AMPs with greater microbicidal activity and reduced toxicity.

Citing Articles

Complex Infections: New Treatment Options in the Antibiotic Pipeline.

Arshad N, Azzam W, Zilberberg M, Shorr A Microorganisms. 2025; 13(2).

PMID: 40005723 PMC: 11858728. DOI: 10.3390/microorganisms13020356.


New Antimicrobial Cyclodepsipeptides from a Freshwater Fungus from the Sierra Madre Oriental in Mexico.

Yeverino I, Bocanegra Sosa T, Aguilar-Vega L, Garcia-Contreras R, Magana-Gonzalez J, Figueroa M ACS Omega. 2025; 10(5):5087-5096.

PMID: 39959071 PMC: 11822689. DOI: 10.1021/acsomega.4c10990.


Diagnostic and therapeutic strategies in combating implanted medical device-associated bacterial biofilm infections.

Amod A, Anurag Anand A, Sahoo A, Samanta S Folia Microbiol (Praha). 2025; .

PMID: 39865215 DOI: 10.1007/s12223-025-01242-y.


Cyclic Peptide MV6, an Aminoglycoside Efficacy Enhancer Against .

Roson-Calero N, Lucas J, Gomis-Font M, de Pedro-Jove R, Oliver A, Balleste-Delpierre C Antibiotics (Basel). 2025; 13(12).

PMID: 39766537 PMC: 11672505. DOI: 10.3390/antibiotics13121147.


Rapid Membrane-Penetrating Hybrid Peptides Achieve Efficient Dual Antimicrobial and Antibiofilm Activity through a Triple Bactericidal Mechanism.

Liu Y, Cui P, Tan R, Ru S ACS Omega. 2024; 9(24):26133-26148.

PMID: 38911764 PMC: 11191078. DOI: 10.1021/acsomega.4c01577.


References
1.
Klubthawee N, Adisakwattana P, Hanpithakpong W, Somsri S, Aunpad R . A novel, rationally designed, hybrid antimicrobial peptide, inspired by cathelicidin and aurein, exhibits membrane-active mechanisms against Pseudomonas aeruginosa. Sci Rep. 2020; 10(1):9117. PMC: 7272617. DOI: 10.1038/s41598-020-65688-5. View

2.
Liu C, Qi J, Shan B, Ma Y . Tachyplesin Causes Membrane Instability That Kills Multidrug-Resistant Bacteria by Inhibiting the 3-Ketoacyl Carrier Protein Reductase FabG. Front Microbiol. 2018; 9:825. PMC: 5938390. DOI: 10.3389/fmicb.2018.00825. View

3.
MacNair C, Stokes J, Carfrae L, Fiebig-Comyn A, Coombes B, Mulvey M . Overcoming mcr-1 mediated colistin resistance with colistin in combination with other antibiotics. Nat Commun. 2018; 9(1):458. PMC: 5792607. DOI: 10.1038/s41467-018-02875-z. View

4.
Olivares J, Bernardini A, Garcia-Leon G, Corona F, Sanchez M, Martinez J . The intrinsic resistome of bacterial pathogens. Front Microbiol. 2013; 4:103. PMC: 3639378. DOI: 10.3389/fmicb.2013.00103. View

5.
Gee M, Burton M, Grevis-James A, Hossain M, McArthur S, Palombo E . Imaging the action of antimicrobial peptides on living bacterial cells. Sci Rep. 2013; 3:1557. PMC: 3609022. DOI: 10.1038/srep01557. View